RE: Musella news letter3 Dec 2025 14:32
According to previous RNS we should get results this year:
“IB003, gallium maltolate (GaM)
Following the recently reported "soft close" of our Phase 1 clinical trial for oral GaM, we anticipate formal closure approval in the near term. In parallel, our clinical team is actively preparing the Phase 1 results for publication and refining the Phase 2 protocol to reflect emerging strategic opportunities.
For the remainder of the current year, our priorities include completing the Phase 1 data analysis, scheduling the End-of-Phase-1 meeting with the U.S. Food and Drug Administration (FDA), integrating their feedback into our development strategy, and evaluating Phase 2 funding pathways, including the option to independently finance.”
It would be nice to get an update from Mike but he seems very quiet, he hasn’t commented on the last few RNS’s indeed we heard from the COO last time which is very unusual. Has anybody heard directly from Mike recently, is he ok? Semantic if you know he is ok it would be good if you could somehow confirm.
Thanks